Physician profile
Paige E Mackenzie
NPI 1437703592
$3,880.75
in general payments reported to CMS, 2019-2025
31 companies · $749 in 2025
The $749 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $1,348 · 2023: $447 · 2024: $775 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.56 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $528.11 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $515.13 | 2021-2024 | Lifevest |
| Abbvie INC. | $407.50 | 2024-2025 | |
| Edwards Lifesciences Corporation | $265.44 | 2021-2023 | Sapien 3 Ultra Resilia |
| Inari Medical, INC. | $213.42 | 2022 | |
| Abbott Laboratories | $206.96 | 2021-2024 | Cardiomems |
| Novo Nordisk INC | $195.48 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $154.09 | 2024-2025 | Entyvio, Eohilia |
| Cordis US Corp. | $137.52 | 2023 | Mynx Control, Rain Sheath Transradial |
| Silk Road Medical, INC. | $136.19 | 2022 | |
| Phathom Pharmaceuticals, INC. | $128.18 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $120.54 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.51 | 2024-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $105.02 | 2024-2025 | Tremfya, Stelara |
| Janssen Pharmaceuticals, INC | $103.03 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $74.70 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $71.91 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $65.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Philips North America LLC | $58.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $51.73 | 2024 | Dupixent |
| Aimmune Therapeutics, INC. | $27.33 | 2025 | Zenpep |
| Biotronik INC. | $26.65 | 2022 | |
| Medtronic, INC. | $22.60 | 2022 | |
| Atricure, INC. | $22.09 | 2023 | |
| Intercept Pharmaceuticals, INC. | $21.60 | 2025 | |
| G Medical Diagnostic Services, INC. | $20.82 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.65 | 2024 | Terlivaz |
| Vivus LLC | $19.88 | 2025 | Pancreaze |
| Gilead Sciences, INC. | $18.56 | 2025 | |
| Pfizer INC. | $18.18 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.97 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Mackenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.